97 related articles for article (PubMed ID: 26722077)
1. Loss of Peroxiredoxin Expression Is Associated with an Aggressive Phenotype in Pancreatic Adenocarcinoma.
Isohookana J; Haapasaari KM; Soini Y; Karihtala P
Anticancer Res; 2016 Jan; 36(1):427-33. PubMed ID: 26722077
[TBL] [Abstract][Full Text] [Related]
2. High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index.
Kuusisto ME; Haapasaari KM; Turpeenniemi-Hujanen T; Jantunen E; Soini Y; Peroja P; Bloigu R; Karihtala P; Kuittinen O
J Clin Pathol; 2015 Jul; 68(7):552-6. PubMed ID: 25935550
[TBL] [Abstract][Full Text] [Related]
3. Peroxiredoxins in breast carcinoma.
Karihtala P; Mäntyniemi A; Kang SW; Kinnula VL; Soini Y
Clin Cancer Res; 2003 Aug; 9(9):3418-24. PubMed ID: 12960131
[TBL] [Abstract][Full Text] [Related]
4. Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas.
Bur H; Haapasaari KM; Turpeenniemi-Hujanen T; Kuittinen O; Auvinen P; Marin K; Koivunen P; Sormunen R; Soini Y; Karihtala P
Histopathology; 2014 Sep; 65(3):319-27. PubMed ID: 24698430
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma.
Kinnula VL; Lehtonen S; Sormunen R; Kaarteenaho-Wiik R; Kang SW; Rhee SG; Soini Y
J Pathol; 2002 Mar; 196(3):316-23. PubMed ID: 11857495
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer.
Cai CY; Zhai LL; Wu Y; Tang ZG
Eur J Surg Oncol; 2015 Feb; 41(2):228-35. PubMed ID: 25434328
[TBL] [Abstract][Full Text] [Related]
7. Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma.
Peroja P; Haapasaari KM; Mannisto S; Miinalainen I; Koivunen P; Leppä S; Karjalainen-Lindsberg ML; Kuusisto ME; Turpeenniemi-Hujanen T; Kuittinen O; Karihtala P
Virchows Arch; 2016 May; 468(5):623-30. PubMed ID: 26983700
[TBL] [Abstract][Full Text] [Related]
8. Peroxiredoxins and their expression in ependymomas.
Haapasalo T; Nordfors K; Järvelä S; Kok E; Sallinen P; Kinnula VL; Haapasalo HK; Soini Y
J Clin Pathol; 2013 Jan; 66(1):12-7. PubMed ID: 23076395
[TBL] [Abstract][Full Text] [Related]
9. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung.
Park JH; Kim YS; Lee HL; Shim JY; Lee KS; Oh YJ; Shin SS; Choi YH; Park KJ; Park RW; Hwang SC
Respirology; 2006 May; 11(3):269-75. PubMed ID: 16635084
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of redox-state-regulating enzymes in melanocytic skin tumours and the surrounding microenvironment.
Hintsala HR; Soini Y; Haapasaari KM; Karihtala P
Histopathology; 2015 Sep; 67(3):348-57. PubMed ID: 25627040
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis.
Pylväs M; Puistola U; Kauppila S; Soini Y; Karihtala P
Eur J Cancer; 2010 Jun; 46(9):1661-7. PubMed ID: 20206498
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of 8-hydroxydeoxyguanosine and peroxiredoxin II in the pathogenesis of endometriosis-associated ovarian cancer.
Sova H; Kangas J; Puistola U; Santala M; Liakka A; Karihtala P
Anticancer Res; 2012 Aug; 32(8):3037-44. PubMed ID: 22843871
[TBL] [Abstract][Full Text] [Related]
13. Peroxiredoxin III protects pancreatic ß cells from apoptosis.
Wolf G; Aumann N; Michalska M; Bast A; Sonnemann J; Beck JF; Lendeckel U; Newsholme P; Walther R
J Endocrinol; 2010 Nov; 207(2):163-75. PubMed ID: 20807727
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer.
Kim YS; Lee HL; Lee KB; Park JH; Chung WY; Lee KS; Sheen SS; Park KJ; Hwang SC
Korean J Intern Med; 2011 Sep; 26(3):304-13. PubMed ID: 22016591
[TBL] [Abstract][Full Text] [Related]
15. Characterization of neural cell types expressing peroxiredoxins in mouse brain.
Jin MH; Lee YH; Kim JM; Sun HN; Moon EY; Shong MH; Kim SU; Lee SH; Lee TH; Yu DY; Lee DS
Neurosci Lett; 2005 Jun; 381(3):252-7. PubMed ID: 15896479
[TBL] [Abstract][Full Text] [Related]
16. Analysis of peroxiredoxin decreasing oxidative stress in hypertensive aortic smooth muscle.
Lee CK; Kim HJ; Lee YR; So HH; Park HJ; Won KJ; Park T; Lee KY; Lee HM; Kim B
Biochim Biophys Acta; 2007 Jul; 1774(7):848-55. PubMed ID: 17556052
[TBL] [Abstract][Full Text] [Related]
17. 8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma.
Soini Y; Haapasaari KM; Vaarala MH; Turpeenniemi-Hujanen T; Kärjä V; Karihtala P
Int J Clin Exp Pathol; 2011 Mar; 4(3):267-75. PubMed ID: 21487522
[TBL] [Abstract][Full Text] [Related]
18. Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer.
Woolston CM; Storr SJ; Ellis IO; Morgan DA; Martin SG
Radiother Oncol; 2011 Aug; 100(2):308-13. PubMed ID: 21641069
[TBL] [Abstract][Full Text] [Related]
19. Oxidative/nitrosative stress and peroxiredoxin 2 are associated with grade and prognosis of human renal carcinoma.
Soini Y; Kallio JP; Hirvikoski P; Helin H; Kellokumpu-Lehtinen P; Kang SW; Tammela TL; Peltoniemi M; Martikainen PM; Kinnula VL
APMIS; 2006 May; 114(5):329-37. PubMed ID: 16725008
[TBL] [Abstract][Full Text] [Related]
20. Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors.
Järvelä S; Rantala I; Rodriguez A; Kallio H; Parkkila S; Kinnula VL; Soini Y; Haapasalo H
BMC Cancer; 2010 Mar; 10():104. PubMed ID: 20307276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
